Avadel pharmaceuticals to host commercial day on june 29 for lumryz™ (sodium oxybate) extended release for oral solution, ciii

Dublin, ireland, june 22, 2023 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a commercial day presentation to provide an overview of its commercial strategy for recently launched lumryz on thursday, june 29, 2023 beginning at 8:00 a.m. et. lumryz was approved by the u.s. food & drug administration (fda) in may 2023 for the treatment of cataplexy or excessive daytime sleepiness (eds) in adults with narcolepsy.
AVDL Ratings Summary
AVDL Quant Ranking